Sam Brusco, Associate Editor08.15.23
Clario, a healthcare research tech firm that provides endpoint technology solutions for clinical trials, has expanded its collaboration with AliveCor.
The new collaboration enables trial participants to collect medical-grade, six-lead ECG reading in their homes via KardiaRx, a clinical-trial-focused app. The technology allows pharma and biotech firms to consider decentralized and hybrid clinical trial strategies in study protocols, which would otherwise have been limited to on-site evaluations.
AliveCor’s KardiaRx app works with its KardiaMobile 6L personal ECG solution, which is wireless, user-friendly, and needs minimal training to use, according to the company. The companion KardiaRx app was integrated into Clario’s clinical trial platform, which lets site personnel provide trial participants with a secure connection code for initial setup and login.
This makes sure that high-quality ECG data is gathered seamlessly, while protecting data and removing the need for participants to create a new account or offer personally identifiable info.
"Our partnership with AliveCor is a game-changer for at-home ECG data collection," Ellen Street, EVP Cardiac Safety & Respiratory at Clario, told the press. "Combining Clario's scientific expertise and 50 years of experience in cardiac safety with AliveCor's focus on customizable app functionality will mean pharmaceutical and biotech customers now have new opportunities to incorporate decentralized or hybrid strategies into their study protocol. This not only enables high-quality data collection but also offers a more diverse pool for recruitment and reduced site visits, and ultimately leads to more successful trials."
"Putting FDA-cleared ECG measurement technology in participants' hands has helped make decentralized clinical trials a reality, and our partnership with Clario brings this capability to even more companies developing the innovative and life-saving therapies of tomorrow," added Patti Baran, SVP of AliveCor. "Applying our remote monitoring solutions to clinical research advances our vision of becoming the premier provider of end-to-end care for participants when they are not in front of a physician."
AliveCor also announced the launch of the world’s first “virtual heart clinic in a box” with partner Luscii this week.
The new collaboration enables trial participants to collect medical-grade, six-lead ECG reading in their homes via KardiaRx, a clinical-trial-focused app. The technology allows pharma and biotech firms to consider decentralized and hybrid clinical trial strategies in study protocols, which would otherwise have been limited to on-site evaluations.
AliveCor’s KardiaRx app works with its KardiaMobile 6L personal ECG solution, which is wireless, user-friendly, and needs minimal training to use, according to the company. The companion KardiaRx app was integrated into Clario’s clinical trial platform, which lets site personnel provide trial participants with a secure connection code for initial setup and login.
This makes sure that high-quality ECG data is gathered seamlessly, while protecting data and removing the need for participants to create a new account or offer personally identifiable info.
"Our partnership with AliveCor is a game-changer for at-home ECG data collection," Ellen Street, EVP Cardiac Safety & Respiratory at Clario, told the press. "Combining Clario's scientific expertise and 50 years of experience in cardiac safety with AliveCor's focus on customizable app functionality will mean pharmaceutical and biotech customers now have new opportunities to incorporate decentralized or hybrid strategies into their study protocol. This not only enables high-quality data collection but also offers a more diverse pool for recruitment and reduced site visits, and ultimately leads to more successful trials."
"Putting FDA-cleared ECG measurement technology in participants' hands has helped make decentralized clinical trials a reality, and our partnership with Clario brings this capability to even more companies developing the innovative and life-saving therapies of tomorrow," added Patti Baran, SVP of AliveCor. "Applying our remote monitoring solutions to clinical research advances our vision of becoming the premier provider of end-to-end care for participants when they are not in front of a physician."
AliveCor also announced the launch of the world’s first “virtual heart clinic in a box” with partner Luscii this week.